Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06523777 · ClinicalTrials.gov registry record
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
A clinical trial of Prostate Cancer, sponsored by Yale University.
- Recruiting
- Registry status
- 350
- Enrollment target
- 7
- Study locations
NCT06523777: Recruiting study of Prostate Cancer, sponsored by Yale University.
NCT06523777 is a study of Prostate Cancer that is actively recruiting participants, run by Yale University. The registered enrollment target is 350 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06523777, a study of Prostate Cancer, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.
Primary Outcome
An 18-item instrument assessing frequency of anxiety in response to prostate cancer with 4 Likert responses ranging from 0 (not at all) to 3 (often); total score range 0 to 54). Higher scores indicate more anxiety.
Conditions Studied
Study Locations (7)
Connecticut
- Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center - Bridgeport
- Griffin Hospital - Derby
- Yale New Haven Health Greenwich Hospital - Greenwich
- Radiology and Biomedical Imaging - New Haven - Smilow Cancer Hospital (North Pavilion): - New Haven
- Saint Raphael's Radiology and Biomedical Imaging, Basement Location. - New Haven
- Yale New Haven Health Lawrence & Memorial Hospital - New London
Rhode Island
- Yale New Haven Health Westerly Hospital - Westerly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2028-07 |
What NCT06523777 shows while recruiting
NCT06523777 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06523777 lists 7 locations in 2 states (Connecticut, Rhode Island).
Frequently Asked Questions
What is clinical trial NCT06523777 about?
NCT06523777 is a clinical study titled "PRISM: Patient Experiences With PET Imaging in Prostate Cancer". The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic c...
What is the current status of trial NCT06523777?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2024-07-25. Estimated completion is 2028-07.
What conditions does trial NCT06523777 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT06523777?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06523777 being conducted?
This trial has 7 study locations across Connecticut, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06523777's enrollment target sits among peer trials
350 146th of 735 higher than 588 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI